Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
about
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitorMechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsFragment screening and HIV therapeuticsDetecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment ScreeningDiscovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid ComplexesHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionVinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activityIdentification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H.Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity.SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirStructure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocketProbing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analysesHuman immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise.Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates."Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on polymerase translocation and inhibition.TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses.Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition.
P2860
Q24650264-88F2A0B6-A24A-407E-B028-1E4800010BD6Q24652511-D13FAB9D-5F49-4FFA-A2E8-2ECCFD941E50Q26826945-3D1A8083-0DA1-435A-BE5A-5706B0AF350BQ27675974-FD44998E-B194-4940-85B0-8C668E3CD2DAQ27678859-5398191A-B071-49FE-857E-FE9195F9CEDCQ28250395-1E8121DB-2DAF-445F-B2B1-76C627261BDEQ28478993-667E1696-470A-48FA-9D59-2F8F640AEEC5Q33373484-6031EE07-A411-4CD6-8405-A51FE321FDC8Q33907525-E63B6461-B8E1-41A9-BC91-1C2E4BAB098CQ34058254-FD7BACE8-FD00-4FC1-90F4-B0D96ED75F40Q34092798-0CD1CDCA-8A5D-453E-91F1-644B4D0CEA3BQ34108782-46CE1DD5-D167-43F5-ABA9-9171B5C99887Q34643481-689313F6-D244-45C6-9AE2-6AD842505779Q34849844-8D2C11D1-6B17-4656-AA61-CD3DB9813149Q35139538-3017144A-5D92-49D2-81BF-50E1700D38DFQ35212611-CFDAAA72-D1DA-4A2F-8036-C9717120EEB0Q35607740-AC3FD605-D64F-4353-B19C-A89B1A41D86FQ35650700-365E9F8B-CEF4-4CD6-8C10-657AB55F1ADBQ35763192-000D86F5-13F6-439E-B959-8E7C78E4049FQ35859394-756770F5-800A-485F-A546-5BEF3C63D83EQ35912746-24B1F5AD-ACCC-4FD5-9443-B5BABD4F8924Q36225123-70958390-9E1A-4B8F-BFDD-29A0E2AB0428Q36388297-A69DAD96-6565-45DC-9CC6-FAD95AEAB22EQ36435971-0F7D13E3-7B3F-4BAA-8D6A-71C5B67BBDC5Q36744634-391E6EAC-C5D2-4575-89F5-A722E5FD9EF0Q36928993-3EC14C7B-C127-4CE3-B947-3E5474B62FAFQ36949351-0175E21F-173F-404E-9136-25A92D48C5B0Q36970906-096496CA-3A6F-4C5D-B51A-920A8C677063Q38212854-591FD2EA-2DBB-482C-B5DF-4B86CA2D1410Q38333617-958583ED-94E4-4FCC-86DE-C7C140DE5936Q39329242-D66ED4EF-48DB-4511-9B36-76300AC50DADQ40251943-4C0D03F8-B130-4707-A44B-F8A937941288Q40748250-E9E61DF2-94D8-49E8-B3E5-AB01EE5A5E8BQ41879018-A2AC76DA-C758-42D6-BDDC-891569C295A9Q42080184-841172B2-4993-4DFC-931D-423E8F850DF4Q42182643-4DA5A933-2988-40E5-96C9-779DA3C5C873Q42739347-B4CDF2C1-F6CB-468B-A7FA-13C3089785FB
P2860
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Indolopyridones inhibit human ...... h a novel mechanism of action.
@ast
Indolopyridones inhibit human ...... h a novel mechanism of action.
@en
type
label
Indolopyridones inhibit human ...... h a novel mechanism of action.
@ast
Indolopyridones inhibit human ...... h a novel mechanism of action.
@en
prefLabel
Indolopyridones inhibit human ...... h a novel mechanism of action.
@ast
Indolopyridones inhibit human ...... h a novel mechanism of action.
@en
P2093
P2860
P356
P1433
P1476
Indolopyridones inhibit human ...... h a novel mechanism of action.
@en
P2093
Bart Kesteleyn
Bertrand Van Schoubroeck
Dirk Jochmans
Eva Bettens
Herwig Van Marck
Inky De Baere
Jérôme Deval
Kurt Hertogs
Marcia Van Ginderen
Maryam Ehteshami
P2860
P304
12283-12292
P356
10.1128/JVI.00889-06
P407
P577
2006-10-04T00:00:00Z